Archive for the Biotech Business Articles

China successfully concludes bird flu virus’ phase II trials

December 25 : Chinese researchers have successfully concluded the second phase of tests with a human vaccine against the deadly bird flu virus, with results showing it to be safe and effective.

Australia puts a price tag on its pain

Nov 19 : Can you put a price tag on pain? Apparently you can. A new study in Australia estimates that pain in the country costs Aus $34.3 billion (US$30.7 billion).

Orchid gets US nod to sell infectious diseases drug

Nov 16 : Chennai-based pharmaceuticals major Orchid Chemicals & Pharmaceuticals Ltd has

Biocon to invest $25 mn on research and development

Oct 31 : Indian biotechnology firm Biocon Ltd Wednesday said they would spend Rs.1 billion ($25.4 million)

Kiwi bio-tech company announces diabetes breakthrough

Oct 24 : A New Zealand bio-tech company has announced the success of a trial transplant

German authorities approve cannabis for MS patient

Sep 3 : Claudia H has become the first German to be allowed legal access to cannabis to treat the multiple sclerosis (MS) she has been suffering from for 14 years.

Elder Pharma acquires stake in Bulgarian firm

Aug 28 : City-based Elder Pharmaceuticals Ltd Tuesday announced acquisition of Biomeda Group of Bulgaria, a leading pharma group, in an all-cash deal worth Euros 5 million.

Innovative medical diagnosis system may help cut cost of screening

Aug. 24 : A team of engineers from Michigan State University has created a medical diagnosis system, which will help axe the cost of screening for a variety of medical problems.

CBI raids Dow Chemical’s Indian subsidiary for graft

Aug 21 : The Central Bureau of Investigation (CBI) Tuesday raided six premises of a subsidiary of leading US firm Dow Chemical and its consultants in the country for allegedly bribing Indian government officials to obtain a licence for its insecticide products.

Dengue vaccine tested in Puerto Rico

Aug 16 : A vaccine designed to immunise people against four strains of dengue fever transmitted by the Aedes aegypti mosquito is undergoing clinical trials in Puerto Rico and could be on the market within a few years.